The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized.
Dr Jennifer Jones and colleagues from Minnesota, USA evaluated the correlations between the Crohn's Disease Activity Index, the Simple Endoscopic Score for Crohn's Disease, and serum high-sensitivity C-reactive protein and interleukin-6, and fecal calprotectin and lactoferrin.
The team enrolled a total of 164 patients with Crohn's disease undergoing colonoscopy.
The researchers found no significant associations between the Crohn's Disease Activity Index and Score for Crohn's Disease scores.
|Serum and fecal biomarkers are associated with endoscopic disease activity |
|Clinical Gastroenterology & Hepatology |
The team also noted no association between the Crohn's Disease Activity Index scores and the serum concentrations of high-sensitivity C-reactive protein and interleukin-6, or the fecal concentrations of calprotectin and lactoferrin.
In contrast, the serum high-sensitivity C-reactive protein, interleukin-6, and the fecal calprotectin and lactoferrin concentrations were higher in patients with more severe endoscopic disease activity.
The team found that the C-reactive protein 717 mutant homozygote and heterozygote status was associated with lower concentrations of high-sensitivity C-reactive protein.
There was a trend toward higher high-sensitivity C-reactive protein concentrations in the C-reactive protein 286 heterozygous adenine mutant-type mutant genotype.
Dr Jones’ team concluded, “Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease.”
“Stimulated high-sensitivity C-reactive protein concentration is affected significantly by select genetic polymorphisms.”